In addition, 46.1% (24/52) of the laboratories routinely carry out EGFR testing on liquid biopsies at both diagnosis and at tumour progression in advanced or metastatic NSCLC, and 25.0% (13/52) at tumour progression only, whereas 28.9% (15/52) of the laboratories do not carry out EGFR testing on liquid biopsies from patients with NSCLC (data not shown). This evidence concerns the gene EGFR and neoplasm.